{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:50Z","timestamp":1791489650527,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":257,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["875171"],"award-info":[{"award-number":["875171"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101446","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:17:29Z","timestamp":1790036249000},"page":"101446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of biomarkers associated with enhanced survival in lung cancer patients undergoing immune checkpoint inhibitor treatment"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3022-9742","authenticated-orcid":false,"given":"Ilse","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1518-7405","authenticated-orcid":false,"given":"Erick","family":"Suazo-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.Jeroen N.","family":"Hiltermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein A.","family":"Heuvelmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hylke C.","family":"Donker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn J.","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101446_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101446_bib0002","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101446_bib0003","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101446_bib0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101446_bib0005","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101446_bib0006","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","article-title":"Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis","volume":"66","author":"von Itzstein","year":"2020","journal-title":"Clin. Chem."},{"issue":"23","key":"10.1016\/j.ctarc.2026.101446_bib0007","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/1759-7714.15401","article-title":"The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"15","author":"Horstman","year":"2024","journal-title":"Thorac. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101446_bib0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-022-00378-0","article-title":"The role of biomarkers in personalized immunotherapy","volume":"10","author":"Sankar","year":"2022","journal-title":"Biomark. Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101446_bib0009","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.21037\/jtd-2019-itm-010","article-title":"Challenges of PD-L1 testing in non-small cell lung cancer and beyond","volume":"12","author":"Wang","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101446_bib0010","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1186\/s12885-020-07690-8","article-title":"Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)","volume":"20","author":"Brueckl","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2026.101446_bib0011","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101446_bib0012","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.path.2023.11.011","article-title":"Microsatellite instability, mismatch repair, and tumor mutation burden in lung cancer","volume":"17","author":"Rosca","year":"2024","journal-title":"Surg. Pathol. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101446_bib0013","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1038\/s41598-023-32499-3","article-title":"Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer","volume":"13","author":"Donker","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101446_bib0014","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43018-019-0008-8","article-title":"Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Nat. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101446_bib0015","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-024-05814-2","article-title":"Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?","volume":"150","author":"Yeghaian","year":"2024","journal-title":"J. Cancer Res. Clin."},{"key":"10.1016\/j.ctarc.2026.101446_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1171649","article-title":"Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors","volume":"14","author":"Ancel","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101446_bib0017","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/cam4.2807","article-title":"Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status","volume":"9","author":"Adachi","year":"2020","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101446_bib0018","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/cancers13071675","article-title":"Prognostic and predictive biomarkers in non-small cell lung cancer patients on immunotherapy-the role of liquid biopsy in unraveling the puzzle","volume":"13","author":"Augustus","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101446_bib0019","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/biomedicines11020508","article-title":"Circulating biomarkers for prediction of immunotherapy response in NSCLC","volume":"11","author":"Goh","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctarc.2026.101446_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102948","article-title":"Systematic review: soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)","volume":"153","author":"Mildner","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101446_bib0021","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12967-019-2122-x","article-title":"The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective","volume":"17","author":"Sidorenkov","year":"2019","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101446_bib0022","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1089\/jpm.2021.0599","article-title":"Eastern cooperative oncology group performance status #434","volume":"25","author":"Mischel","year":"2022","journal-title":"J. Palliat. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101446_bib0023","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5395\/rde.2013.38.1.52","article-title":"Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis","volume":"38","author":"Kim","year":"2013","journal-title":"Restor. Dent. Endod."},{"key":"10.1016\/j.ctarc.2026.101446_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112152","article-title":"The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: data from a retrospective cohort study","volume":"134","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101446_bib0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2022.6901","article-title":"Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy","volume":"9","author":"Voruganti","year":"2023","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101446_bib0026","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.21873\/invivo.13340","article-title":"Smoking status at time of diagnosis affects the efficacy of anti-PD-1\/L1 therapy in patients with advanced NSCLC","volume":"37","author":"Kim","year":"2023","journal-title":"In Vivo (Brooklyn)"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101446_bib0027","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00262-022-03320-3","article-title":"Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade","volume":"72","author":"Jain","year":"2023","journal-title":"Cancer Immunol. Immun."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101446_bib0028","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jtho.2016.05.024","article-title":"Clinicopathologic features of advanced squamous NSCLC","volume":"11","author":"Socinski","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101446_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107594","article-title":"The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis","volume":"96","author":"Mo","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"40","key":"10.1016\/j.ctarc.2026.101446_bib0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J. Open Source Softw."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101446_bib0031","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3892\/ol.2023.13740","article-title":"Pretreatment levels of serum alkaline phosphatase are associated with the prognosis of patients with non\u2011small cell lung cancer receiving immune checkpoint inhibitors","volume":"25","author":"Yang","year":"2023","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101446_bib0032","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cam4.2024","article-title":"Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101446_bib0033","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1183\/20734735.006911","article-title":"Prognostic and predictive factors for lung cancer","volume":"9","author":"Paesmans","year":"2012","journal-title":"Breathe"},{"key":"10.1016\/j.ctarc.2026.101446_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.625417","article-title":"Serum creatinine as a potential biomarker of skeletal muscle atrophy in non-small cell lung cancer patients","volume":"12","author":"das Neves","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ctarc.2026.101446_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101446_bib0036","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00262-023-03436-0","article-title":"Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients","volume":"72","author":"\u00d6zdemir","year":"2023","journal-title":"Cancer Immunol. Immun."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101446_bib0037","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-023-02482-w","article-title":"Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases","volume":"130","author":"Qu","year":"2024","journal-title":"Br. J. Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:41:33Z","timestamp":1791488493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"alternative-id":["S2468294226003564"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101446","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of biomarkers associated with enhanced survival in lung cancer patients undergoing immune checkpoint inhibitor treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101446"}}